# Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

> **NCT00131911** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 93 (actual)

## Conditions studied

- Gastrinoma
- Glucagonoma
- Insulinoma
- Metastatic Gastrointestinal Carcinoid Tumor
- Neuroendocrine Tumor
- Pancreatic Polypeptide Tumor
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Islet Cell Carcinoma
- Somatostatinoma
- WDHA Syndrome

## Interventions

- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00131911
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2010-10
- **Final completion:** 2013-04
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131911, "Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00131911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*